RPS6P25

Across TCGA pan-cancer cohorts, RPS6P25 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of RPS6P25’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where RPS6P25 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPS6P25 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

COAD, LIHC, and KIRC are the cancer types where RPS6P25 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPS6P25 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	+2.413	<.001	11	view →
LIHC	Female	II,III,IV	+0.574	<.001	6	view →
KIRC	Male	All	+0.235	<.001	6	view →
READ	All	All	+0.840	<.001	5	view →
LUAD	Female	All	+0.489	<.001	5	view →
CHOL	All	All	+0.747	.003	4	view →
LUSC	Male	II,III,IV	+0.423	<.001	4	view →
PRAD	All	All	+0.292	.001	2	view →
THCA	All	All	−0.161	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

RPS6P25–COAD

Open the COAD breakdown →